On June 6, 2016 Stemline Therapeutics, Inc. (Nasdaq:STML) reported that Ivan Bergstein, M.D., Stemline’s CEO, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 10:00 AM ET (Press release, Stemline Therapeutics, JUN 6, 2016, View Source [SID:1234513078]). During the presentation, Dr. Bergstein will discuss the SL-401 Phase 2 blastic plasmacytoid dendritic cell neoplasm (BPDCN) data presented on June 4th at the 2016 ASCO (Free ASCO Whitepaper) conference. He will also review next steps for the SL-401 program as well as provide updates on the company’s overall pipeline. A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!